Issue 53

Cybin CEO Doug Drysdale on investor opportunities in psychedelic healthcare

Cybin became the first psychedelic healthcare company to list on the New York Stock Exchange, with its psilocybin formulation to treat Major Depressive Disorder in Phase II clinical trials.

The company’s CEO, Doug Drysdale, has 30 years’ experience in the healthcare sector and has raised US$4 billion in public and private capital. PSYCH spoke to Drysdale on raising finance for psychedelic medicines, industry trends and the emerging investment opportunities.

Read More

DETROIT VOTES TO DECRIMINALISE PSYCHEDELICS

Detroit has become the latest large city in the US to decriminalise the use of psychedelic medicines.

Read More

STUDY LOOKS TO DEFEAT GAMBLING ADDICTION WITH PSYCHEDELICS

Forbes spoke with Awakn’s Chief Research Officer, Professor David Nutt, on treating addiction disorders.

Read More

BUSINESS AND INVESTMENT

Wavepaths raises US$4.5m in seed round.

Small Pharma reports 2021 Q2 financials.

Bright Minds Biosciences starts trading on the Nasdaq.

LOVE Pharma lists on Canadian Stock Exchange.

Levitee Labs acquires Canadian clinics and pharmacies.

Awakn provides update on drug development programme.

atai shares update from Phase IIa clinical trial.

COMPASS to launch COMP360 Phase II trial to treat PTSD.

MINDCURE signs LOI with Awakn to distribute ketamine protocol.

FDA approves Filament Health’s Phase I clinical trial.

Entheon Biomedical shares update from clinical trials.

FDA approves Nova Mentis orphan drug designation.

Algernon Pharmaceuticals shares pre-clinical data.

Incannex and Monash University gain approval for psilocybin study.

MYND acquires Cava’s psychedelic IP portfolio.

Mydecine files drug delivery patent.

Pasithea Therapeutics treats its first patients in UK with ketamine therapy.

Tryp submits IND application for Phase IIa clinical trial.

PharmaTher provides update on drug delivery research.

Red Light Holland appoints new CFO.

Beckley Psytech appoints former Janssen VP as Chief Medical Officer.

The Psychedelics as Medicine Report: Third Edition

The 200+ page Psychedelics as Medicine Report: Third Edition is the most comprehensive analysis of the psychedelic healthcare industry, empowering investors, operators and regulators to make informed decisions.

Key findings:

  • The medical psychedelic market is valued at US$190 million, and is expected to exceed US$2.4 billion by 2026.
  • Investment in psychedelic companies has now surpassed US$2 billion.
  • Two-thirds of North Americans and Europeans support the legalisation of psychedelic-assisted therapy.
Download your complimentary copy

SCIENCE AND RESEARCH

Silo Pharma enters research agreement with Columbia University.

Psychedelics & mental health: This may be the next big thing in pharma.

What a ketamine ‘trip’ for depression is really like.

PharmaTher enters research collaboration with Revive Therapeutics.

The people turning to psychedelics on their deathbeds.

The potential of psilocybin to transform the mental healthcare landscape.

REGULATION AND LEGISLATION

Italian activists submit 500,000 signatures for legalisation of psychedelic medicines.

Why the push to decriminalise psychedelics is growing in Michigan.